BioSpace News Archive

Chinese biotech company Ascletis Pharma debuted on the Hong Kong stock exchange, rising as much as 6.4 percent, but ending the day where it started.

VisCardia Inc. announced today the first implant of the VisONE® implantable system for heart failure, and the commencement of its VisONE Heart Failure pilot study in Ukraine.

MabVax Therapeutics Holdings, Inc. announced that four members of the Company’s Board of Directors have resigned from their positions effective as of July 31, 2018.

BioTime shareholders will receive one share of AgeX common stock for every 10 shares of BioTime common stock held

CalciMedica announced that the first patients in a Phase 2a clinical study for acute pancreatitis have been dosed with its proprietary calcium release-activated calcium (CRAC) channel inhibitor CM4620.

Virtus Pharmaceuticals, LLC continues its efforts to provide consumers with access to lower cost drugs in the pharmaceutical industry, this time by prevailing in a case against Bausch Health Companies (formerly Valeant Pharmaceuticals) for chlordiazepoxide/clidinium products prescribed to treat various stomach and intestinal conditions.

TherapeuticsMD, Inc. (NASDAQ: TXMD) today announced the pricing of its previously announced $65 million underwritten public offering of common stock at a price to the public of $5.10 per share.

Reports 13% Consolidated GAAP Earnings Per Diluted Share Growth

Tocagen Inc. announced it will report its second quarter 2018 financial results and business progress on Tuesday, August 7, 2018, after the close of the U.S. financial markets.

Worldwide revenue of $51.8 million – an increase of 14.5% year over year